Phase IIa (cohort expansion) is an open label randomised study. primaryPurpose: TREATMENT masking: NONE count: 220 type: ESTIMATED name: IPN01194 name: IPN01194 measure: Phase 1: Percentage of participants with dose limiting toxicity (DLT) measure: Phase 1: Percentage of participants experiencing Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TE SAEs) measure: Phase 1: Percentage of participants with dose interruptions and permanent treatment discontinuations measure: Phase 2a: Objective response rate (ORR) measure: Phase 1: Time to maximum observed drug concentration (Tmax) after single and multiple doses of IPN01194 measure: Phase 1: Maximum observed drug concentration (Cmax) after single and multiple doses of IPN01194 measure: Phase 1: Area under the plasma concentration time curve (AUCtau) after single and multiple doses of IPN01194 measure: Phase 1: Geometric mean ratio of Cmax of IPN01194 administered in fed state relative to fasted state measure: Phase 1: Geometric mean ratio of AUClast of IPN01194 administered in fed state relative to fasted state measure: Phase 1: Geometric mean ratio of AUCinf administered in fed state relative to fasted state measure: Phase 1: Prolongation of corrected QT interval (QTc) measure: Phase 1: Objective response rate (ORR) measure: Phase 2a: Duration of response (DoR) measure: Phase 2a: Progression-free survival (PFS) measure: Phase 2a: PFS rate at 4 months measure: Phase 2a: Disease control rate (DCR) measure: Phase 2a: Percentage of participants with TEAEs and TE SAEs measure: Phase 2a: Percentage of participants with dose interruptions and permanent treatment discontinuations sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Angeles Clinic and Research Institute - California status: NOT_YET_RECRUITING city: Los Angeles state: California zip: 90025 country: United States lat: 34.05223 lon: -118.24368 facility: UC San Diego Health System - La Jolla status: NOT_YET_RECRUITING city: San Diego state: California zip: 92037 country: United States lat: 32.71533 lon: -117.15726 facility: Yale Cancer Center - New Heaven status: NOT_YET_RECRUITING city: New Haven state: Connecticut zip: 06510 country: United States lat: 41.30815 lon: -72.92816 facility: Sarah Cannon Research Institute (SCRI) - Nashville status: NOT_YET_RECRUITING city: Nashville state: Tennessee zip: 37203 country: United States lat: 36.16589 lon: -86.78444 facility: Virginia Cancer Specialist status: RECRUITING city: Fairfax state: Virginia zip: 22031 country: United States lat: 38.84622 lon: -77.30637 facility: Centre Léon Bérard - Lyon status: NOT_YET_RECRUITING city: Lyon country: France lat: 45.74848 lon: 4.84669 facility: Paris Saint-Louis status: NOT_YET_RECRUITING city: Paris country: France lat: 48.85341 lon: 2.3488 facility: Institut de Cancerologie de l'Ouest (St-Herblain) status: NOT_YET_RECRUITING city: Saint-Herblain country: France lat: 47.21765 lon: -1.64841 facility: IGR-Villejuif status: NOT_YET_RECRUITING city: Villejuif country: France lat: 48.7939 lon: 2.35992 facility: Barcelona - Val D'Hebron status: NOT_YET_RECRUITING city: Barcelona country: Spain lat: 41.38879 lon: 2.15899 facility: Fundacion Jimenez Diaz - Madrid status: NOT_YET_RECRUITING city: Madrid country: Spain lat: 40.4165 lon: -3.70256 facility: M.D. Anderson Cancer Center Madrid status: NOT_YET_RECRUITING city: Madrid country: Spain lat: 40.4165 lon: -3.70256 hasResults: False